Coldstream Capital Management Inc. Invests $230,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Coldstream Capital Management Inc. bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,109 shares of the medical equipment provider’s stock, valued at approximately $230,000.

Several other hedge funds have also recently added to or reduced their stakes in LNTH. Moloney Securities Asset Management LLC acquired a new position in shares of Lantheus during the third quarter valued at $1,066,000. Geode Capital Management LLC grew its position in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in Lantheus during the 2nd quarter valued at about $290,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus during the 3rd quarter worth about $25,955,000. Finally, Van ECK Associates Corp lifted its stake in shares of Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 0.5 %

LNTH opened at $93.48 on Tuesday. The firm has a market cap of $6.50 billion, a PE ratio of 15.55 and a beta of 0.45. The business has a fifty day simple moving average of $97.62 and a 200-day simple moving average of $98.20. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Wall Street Analyst Weigh In

A number of research firms recently commented on LNTH. JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $130.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.